Search results
No hormones, no problem: YourChoice’s first-of-its-kind male birth control is safe for men, so far
FierceBiotech· 1 day agoYourChoice Therapeutics on June 4 at the BIO International Conference in San Diego will share phase ...
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion...
Char-Koosta News· 3 days ago("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
KOLR - KSFX Ozarks· 4 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced ...
Current spectral norm and phase variation based fault region identification for active distribution...
Nature· 3 days agoThe paper presents a fault region identification method for the active distribution network (ADN) with limited PMU. First, PMU configuration and region division strategies are proposed based ...
Caleb Williams cadence mastery is vital top priority for rookie early in Bears' QB development plan
NBC Sports Chicago via Yahoo Sports· 52 minutes agoCaleb Williams is working to "find his voice" with the Bears. While mastering the cadence will take...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral...
Morningstar· 7 days agoSHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 19 hours agoGHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today announced new data demonstrating that its antibodies
Rgenta Therapeutics Presents Preclinical Data from Lead Program RGT-61159, a Potent Inhibitor of...
The Pilot News· 5 days agoRgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules for therapeutic RNA modification for oncology and CNS disorders, today announced ...
Centroid of the bacterial growth curves: a metric to assess phage efficiency - Communications...
Nature· 5 days agoIn mathematics or physics, the center of gravity, is the specific location where the combined effect of an object’s weight produces no net moment. This equilibrium condition would allow a rigid ...
Asia-Pacific’s Shifting Engine Industry Dynamics
Aviation Week· 7 days agoAt Aviation Week Network’s Aero-Engines Asia-Pacific in April, MRO leaders discussed the challenges in the engine market in their region despite strong demand and impressive growth. Leaders ...
